A Research Trial of Aralast NP in New Onset Diabetes (RETAIN) - Part II

PHASE2WithdrawnINTERVENTIONAL
0
Timeline

Start Date

October 31, 2010

Primary Completion Date

August 31, 2014

Study Completion Date

August 31, 2014

Conditions
Diabetes Mellitus, Type 1
Interventions
DRUG

Aralast NP

Participants will receive IV infusions of Aralast NP (90mg/kg) once a week for 12 weeks.

DRUG

Placebo

Participants will receive IV infusions of placebo once a week for 12 weeks.

Trial Locations (15)

10027

Columbia University, New York

19104

The Children's Hospital of Philadelphia, Philadephia

20678

Calvert Memorial Hospital, Prince Frederick

21201

University of Maryland Medical Center, Baltimore

30309

Atlanta Diabetes Associates, Atlanta

30322

Emory University, Atlanta

43205

Nationwide Children's Hospital, Columbus

52242

University of Iowa, Iowa City

78229

Cetero Research San Antonio, San Antonio

80045

Barbara Davis Center, Aurora

92093

University of California San Diego, La Jolla

06511

Yale University, New Haven

02114

Massachusetts General Hospital, Boston

02215

Joslin Diabetes Center, Boston

01655

University of Massachusetts Medical School, Worchester

Sponsors
All Listed Sponsors
collaborator

Immune Tolerance Network (ITN)

NETWORK

collaborator

Juvenile Diabetes Research Foundation

OTHER

lead

National Institute of Allergy and Infectious Diseases (NIAID)

NIH